The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction.
Igor A. Astsaturov
No relevant relationships to disclose
Joshua E. Meyer
No relevant relationships to disclose
Jonathan D. Cheng
No relevant relationships to disclose
Anthony J. Olszanski
No relevant relationships to disclose
Holly Dushkin
No relevant relationships to disclose
Adam C. Berger
No relevant relationships to disclose
Monica Davey
No relevant relationships to disclose
Steven J. Cohen
No relevant relationships to disclose
Barbara Burtness
No relevant relationships to disclose
Walter Joseph Scott
No relevant relationships to disclose